Lymphomas in adolescents and young adults represent approximately one quarter of all cancers in this age group. Historically, adolescent and young adult cancer patients represent a unique population with diverging issues surrounding psychosocial hardships/barriers, economics, and lack of standardization of therapeutic approaches.
Furthermore, the biologic differences within the adolescent and young adult population seen in various lymphoma subtypes likely play a role in overall outcomes for this group. Without an organized approach to clinical and translational research for adolescent and young adult patients within specialized treatment centers, this population may continue to experience inferior results. Here we look at the current perspectives of adolescent and young adult lymphomas with respect to disease biology, clinical characteristics, treatment, and prognosis of this unique lymphoma population.
From the Departments of *Pediatrics,
§Microbiology & Immunology, and
∥Cell Biology & Anatomy, Maria Fareri Children's Hospital, New York Medical College, Valhalla, NY.
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. M.S.C. reports funding from the Pediatric Cancer Research Foundation, St. Baldrick's Foundation, and the Marisa Fund.
Reprints: Mitchell S. Cairo, MD, New York Medical College, 40 Sunshine Cottage Rd, Skyline IN-D12, Valhalla, NY 10595. E-mail: Mitchell_Cairo@NYMC.edu.
Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.journalppo.com).